AU2016334875B2 - Blood preparation and profiling - Google Patents

Blood preparation and profiling Download PDF

Info

Publication number
AU2016334875B2
AU2016334875B2 AU2016334875A AU2016334875A AU2016334875B2 AU 2016334875 B2 AU2016334875 B2 AU 2016334875B2 AU 2016334875 A AU2016334875 A AU 2016334875A AU 2016334875 A AU2016334875 A AU 2016334875A AU 2016334875 B2 AU2016334875 B2 AU 2016334875B2
Authority
AU
Australia
Prior art keywords
proteins
blood
protein
red blood
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016334875A
Other languages
English (en)
Other versions
AU2016334875A8 (en
AU2016334875A1 (en
Inventor
Ben Herbert
Cameron Hill
Elisabeth KARSTEN
Alan Liddle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangui Bio Pty Ltd
Original Assignee
Sangui Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904075A external-priority patent/AU2015904075A0/en
Application filed by Sangui Bio Pty Ltd filed Critical Sangui Bio Pty Ltd
Publication of AU2016334875A1 publication Critical patent/AU2016334875A1/en
Publication of AU2016334875A8 publication Critical patent/AU2016334875A8/en
Application granted granted Critical
Publication of AU2016334875B2 publication Critical patent/AU2016334875B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5421—IL-8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2016334875A 2015-10-07 2016-10-06 Blood preparation and profiling Active AU2016334875B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015904075A AU2015904075A0 (en) 2015-10-07 Blood preparation and profiling
AU2015904075 2015-10-07
PCT/AU2016/000341 WO2017059477A1 (en) 2015-10-07 2016-10-06 Blood preparation and profiling

Publications (3)

Publication Number Publication Date
AU2016334875A1 AU2016334875A1 (en) 2018-04-26
AU2016334875A8 AU2016334875A8 (en) 2018-05-10
AU2016334875B2 true AU2016334875B2 (en) 2022-10-27

Family

ID=58487130

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016334875A Active AU2016334875B2 (en) 2015-10-07 2016-10-06 Blood preparation and profiling

Country Status (10)

Country Link
US (2) US11243218B2 (enExample)
EP (2) EP4009047A1 (enExample)
JP (3) JP6824994B2 (enExample)
KR (1) KR102632490B1 (enExample)
CN (2) CN108700565B (enExample)
AU (1) AU2016334875B2 (enExample)
CA (1) CA3001154C (enExample)
HK (1) HK1258470A1 (enExample)
SG (1) SG11201802754XA (enExample)
WO (1) WO2017059477A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009369A1 (en) 2015-12-22 2017-06-29 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
WO2018112500A1 (en) * 2016-12-20 2018-06-28 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
US20240352423A1 (en) * 2021-03-10 2024-10-24 Terasaki Institute For Biomedical Innovation Methods and systems of producing products such as animal derived products
CN114081899A (zh) * 2021-11-02 2022-02-25 四川大学华西医院 一种富白细胞富血小板血浆的制备方法
US20250085283A1 (en) 2022-03-23 2025-03-13 Teijin Limited Method for quantifying nicotinamide adenine dinucleotide (nad+) or nicotinamide mononucleotide (nmn), and kit and filter paper for performing the method
WO2024010763A1 (en) * 2022-07-07 2024-01-11 Russell Biotech, Inc. Preparation of platelet free mononuclear cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156806A2 (en) * 2012-04-20 2013-10-24 Advancell Diagnosztika Kft Quantitative biomarkers in the erythrocyte membrane

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931276A (en) 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
WO1992005801A1 (en) 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
ES2167391T3 (es) * 1994-09-16 2002-05-16 Merck Patent Gmbh Inmunoconjugados ii.
US5763280A (en) * 1997-01-21 1998-06-09 Coulter International Corp. Cyanide-free lytic reagent composition and method for hemoglobin and cell analysis
FR2778851B1 (fr) 1998-05-19 2002-07-26 Aetsrn Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
US8431117B2 (en) 1999-08-30 2013-04-30 David S Terman Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects
AU2001272670A1 (en) 2000-07-24 2002-02-05 Gendel Limited Polypeptide delivery II-2
PT1495328E (pt) 2002-04-16 2014-09-09 Vlaams Interuniv Inst Biotech Um marcador para medir cirrose hepática
US7501286B2 (en) 2002-08-14 2009-03-10 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US7276382B2 (en) * 2003-10-02 2007-10-02 Noboru Horiguchi Blood testing method
GB0325483D0 (en) 2003-10-31 2003-12-03 Plasmacute As Assay
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US7378054B2 (en) 2004-04-16 2008-05-27 Savvipharm Inc Specimen collecting, processing and analytical assembly
US7803523B2 (en) * 2004-08-27 2010-09-28 University Health Network Whole blood preparation for cytometric analysis of cell signaling pathways
US20060166223A1 (en) 2005-01-26 2006-07-27 Reed Michael W DNA purification and analysis on nanoengineered surfaces
WO2006123253A2 (en) 2005-03-29 2006-11-23 Inverness Medical Switzerland Gmbh Device and method of monitoring a patient
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US8530182B2 (en) 2007-12-05 2013-09-10 Centers For Disease Control And Prevention Viral protein quantification process and vaccine quality control therewith
US20110245092A1 (en) 2008-03-04 2011-10-06 John Bilello Diagnosing and monitoring depression disorders based on multiple serum biomarker panels
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
EP2442641A4 (en) 2009-06-16 2016-03-09 Univ Columbia METHOD FOR REDUCING SIDE EFFECTS OF THE TRANSFUSION OF AGED RED BLOOD CELLS
JP6162359B2 (ja) * 2009-06-30 2017-07-12 株式会社カネカ 血液成分の分離システム、分離材
EP2464966A1 (en) 2009-08-13 2012-06-20 Basf Se Means and methods for diagnosingthyroid disorders
US20130202625A1 (en) 2010-01-21 2013-08-08 The Regents Of The University Of Californa Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
SG183195A1 (en) 2010-02-08 2012-09-27 Piramal Imaging Sa F18-tyrosine derivatives for imaging bone metastases
WO2011127056A2 (en) 2010-04-05 2011-10-13 The Uab Research Foundation Biomarkers for assessing exposure to ionizing radiation and absorbed dose
SG195180A1 (en) 2011-05-31 2013-12-30 Singapore Health Serv Pte Ltd Method for detecting disease biomarkers
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
CN104394884A (zh) 2012-03-21 2015-03-04 爱瑞泰克药物公司 用于治疗急性髓细胞白血病(aml)的药剂
EP2872154B1 (en) 2012-07-11 2017-05-31 Sangamo BioSciences, Inc. Methods and compositions for delivery of biologics
EP2994117B1 (en) 2013-05-10 2023-06-07 EryDel S.p.A. Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
JP6383920B2 (ja) * 2013-09-11 2018-09-05 有限会社ピコデバイス パーキンソン病の判定基準とする方法
CN106255884B (zh) * 2013-10-04 2019-01-11 赛尔爱迪尔私人有限公司 用于细胞治疗的生物标志物
KR101845588B1 (ko) 2014-04-07 2018-04-05 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장
BR122021024421B1 (pt) 2015-05-18 2022-05-03 Hemanext Inc Usos de um produto de sangue total armazenado reduzido de oxigênio com plaquetas
CA3009369A1 (en) 2015-12-22 2017-06-29 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
WO2018112500A1 (en) 2016-12-20 2018-06-28 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156806A2 (en) * 2012-04-20 2013-10-24 Advancell Diagnosztika Kft Quantitative biomarkers in the erythrocyte membrane

Also Published As

Publication number Publication date
CA3001154C (en) 2023-10-17
EP3359962B1 (en) 2021-11-17
SG11201802754XA (en) 2018-05-30
KR20180083853A (ko) 2018-07-23
KR102632490B1 (ko) 2024-02-02
US20180306817A1 (en) 2018-10-25
HK1258470A1 (zh) 2019-11-15
US11243218B2 (en) 2022-02-08
US20240060997A1 (en) 2024-02-22
JP2018530766A (ja) 2018-10-18
CN114019171A (zh) 2022-02-08
AU2016334875A8 (en) 2018-05-10
WO2017059477A1 (en) 2017-04-13
AU2016334875A1 (en) 2018-04-26
JP2023078210A (ja) 2023-06-06
EP3359962A1 (en) 2018-08-15
CA3001154A1 (en) 2017-04-13
CN108700565B (zh) 2021-10-29
CN108700565A (zh) 2018-10-23
EP3359962A4 (en) 2019-03-06
JP6824994B2 (ja) 2021-02-03
EP4009047A1 (en) 2022-06-08
JP2021073453A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
US20240060997A1 (en) Blood Preparation and Profiling
JP7425903B2 (ja) プロテアーゼインヒビターを用いる血液プロファイリング
Hosseini et al. Diminished frequency of menstrual and peripheral blood NKT-like cells in patients with unexplained recurrent spontaneous abortion and infertile women
Koutsokera et al. Acute cellular rejection: is it still relevant?
Galati et al. Circulating dendritic cells are severely decreased in idiopathic pulmonary fibrosis with a potential value for prognosis prediction
Mostafa et al. Up-regulated serum levels of interleukin (IL)-17A and IL-22 in Egyptian pediatric patients with COVID-19 and MIS-C: Relation to the disease outcome
Blot et al. Specific features of the coagulopathy signature in severe COVID-19 pneumonia
Simmalee et al. Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review
Iacobescu et al. Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants
US20210123919A1 (en) Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist
Kallankari et al. Chemokine CCL18 predicts intraventricular hemorrhage in very preterm infants
WO2019117132A1 (ja) がん免疫療法の予後予測のためのバイオマーカー
Renert‐Yuval et al. Eosinophils in hidradenitis suppurativa patients exhibit pro‐inflammatory traits, implicating a potential pathogenic role in the disease
Atere et al. Prognostic roles of c-reactive protein and erythrocyte sedimentation rate as acute phase reactants in mentally challenged subjects
AU2022204237A1 (en) Flow based assays for therapeutics
Sato et al. Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis
US20240393322A1 (en) Methods for detecting heavy metals in biological samples
Priya Dharshani et al. Pattern of Circulating Mesenchymal Stromal Cells and Hematopoietic Progenitor and Stem Cells in the Peripheral Blood of Trauma Patients with and without Hemorrhagic Shock
Fric ACCELERATED AGING OF IMMUNE SYSTEM IN NEUROBLASTOMA SURVIVORS-CLINICAL PHENOMENON
Linge et al. P28 Decreased platelet size in systemic lupus erythematosus is associated with up-regulation of type I interferon proteins

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 16 , PAGE(S) 2272 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SANGUI BIO PTY LTD, APPLICATION NO. 2016334875, UNDER INID (71) CORRECT THE APPLICANT NAME TO SANGUI BIO PTY. LTD

FGA Letters patent sealed or granted (standard patent)